Prognostic significance of Vascular Endothelial Growth Factor protein levels in oral and oropharyngeal squamous cell carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2046-2052

  Smith, Benjamin D ^a   Smith, Grace L ^a   Carter, Darryl ^a   Sasaki, Clarence T ^a   Haffty, Bruce G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 0034111116     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2046     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. Smith BD, Haffty BG: Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Invest 7:125-144, 1999
3. Shin DM, Lee JS, Lippman SM, et al: p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519-529, 1996
4. Caminero MJ, Nunez F, Suarez C, et al: Detection of p53 protein in oropharyngeal carcinoma: Prognostic implications. Arch Otolaryngol Head Neck Surg 122:769-772, 1996
5. Raybaud-Diogene H, Fortin A, Morency R, et al: Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J Clin Oncol 15: 1030-1038, 1997
6. Hedge PU, Brenski AC, Caldarelli DD, et al: Tumor angiogenesis and p53 mutations: Prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 124:80-85, 1998
7. Meredith SD, Levine PA, Burns JA, et al: Chromosome 11q13 amplification in head and neck squamous cell carcinoma: Association with poor prognosis. Arch Otolaryngol Head Neck Surg 121:790-794, 1995
8. Bellacosa A, Almadori G, Cavallo S, et al: Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: Prognostic significance and clinical implications. Clin Cancer Res 2:175-180, 1996
9. Akervall JA, Michalides RJ, Mineta H, et al: Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:380-389, 1997
10. Kyomoto R, Kumazawa H, Toda Y, et al: Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer 74:576-581, 1997
11. Pignataro L, Pruneri G, Carboni N, et al: Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 16:3069-3077, 1998
12. Nogueira CP, Dolan RW, Gooey J, et al: Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope 108:345-350, 1998
13. Michalides RJ, van Veelen NM, Kristel PM, et al: Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 123:497-502, 1997
14. Grandis JR, Melhem M, Gooding W, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
15. Dassonville O, Formenta J, Francoual M, et al: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11:1873-1878, 1993
16. Wen QH, Miwa T, Yoshizaki T, et al: Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 106:884-885, 1996
17. Maurizi M, Almadori G, Ferrandina G, et al: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74:1253-1257, 1996
18. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
19. Folkman J: Tumor angiogenesis. Adv Cancer Res 43:175-203, 1985
20. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Ann Rev Physiol 53:217-239, 1991
21. Denhart BC, Guidi AJ, Tognazzi K, et al: Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77:659-664, 1997
22. Klagsbrun M, Soker S: VEGF/VPF: The angiogenesis factor found? Curr Biol 3:699-702, 1993
23. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992
24. Shweiki D, Itin A, Softer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
25. Shweiki D, Neeman M, Itin A, et al: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci USA 92:768-772 1995
26. Hlatky L, Tsionou C, Hahnfeldt P, et al: Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 54:6083-6086, 1994
27. Kroll J, Waltenberger J: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272:32521-32527, 1997
28. Linderholm B, Tavelin B, Grankvist K, et al: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128, 1998
29. Eppenberger U, Kueng W, Schlaeppi JM, et al: Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-3136, 1998
30. Eisma RJ, Spiro JD, Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174:513-517, 1997
31. Maeda T, Matsumura S, Hiranuma H, et al: Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumor progression and p53 gene status. J Clin Pathol 51:771-775, 1998
32. Salven P, Heikkila P, Anttonen A, et al: Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance. Mod Pathol 10:1128-1133, 1997
33. Haffty B, Son YH, Papac R, et al: Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol 15:268-276, 1997
34. Haffty BG, Son YH, Wilson LD, et al: Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Invest 5:235-245, 1997
35. American Joint Committee on Cancer: Manual for Staging Cancer (ed 4). Philadelphia, PA, JB Lippincott, 1992
36. Bryce TJ, Dewhirst MW, Floyd CE, et al: Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 41:339-345, 1998
37. Strauss M, Saccogna PW, Allphin AL: Cephazolin and metronidazole prophylaxis in head and neck surgery. J Laryngol Otol 111:631-634, 1997
38. Hussain M, Kish JA, Crane L, et al: The role of infection in the morbidity and mortality of patients with head and neck cancer undergoing multimodality therapy. Cancer 67:716-721, 1991
39. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991